Adjuvant nivolumab plus chemoradiotherapy “could be proposed as a new standard treatment,” said Jean Bourhis, MD, PhD.

A retrospective, real-world data analysis from the TriNetX database sought to determine rates of venous thromboembolism and survival outcomes in patients with multiple myeloma who were treated with ...

A systematic review of the literature explored the impact of interventions on family dynamics in families of children with cancer.

There is a high unmet need for effective neoadjuvant treatments for muscle-invasive bladder cancer for patients who cannot tolerate or refuse cisplatin chemotherapy.

Investigators studied the effect of immunotherapy on overall survival among women with genital tract melanoma.

HealthDay News — For pediatric patients with retinoblastoma, aqueous humor liquid biopsy via anterior chamber paracentesis is a safe and well-tolerated procedure, according to a study recently ...

BSO not associated with increased risk for cardiovascular diseases, ischemic heart disease, or cerebrovascular disease.

Various factors contribute to disparities in 30-day readmission rates following allogeneic hematopoietic stem cell transplantation (allo-HCT) among patients with acute myeloid leukemia (AML), ...

Most-favored-nation pricing is “founded on incorrect assumptions about where high out-of-pocket costs really come from and what it would mean for the US to adopt cost-effectiveness standards used by ...

Using the COMPASS model, researchers project risk of cardiac late effects for survivors of pediatric ALL at age 50 years.

Rusfertide could be a new treatment option for patients with polycythemia vera, according to Andrew Kuykendall, MD.

Researchers sought to determine whether the ALL-Hematotox would be able to predict hematotoxicity for patients with B-ALL who are at risk of severe hematotoxicity following CAR-T therapy.